As of close of business last night, Standard BioTools Inc’s stock clocked out at $2.92, up 1.39% from its previous closing price of $2.88. In other words, the price has increased by $+0.0400 from its previous closing price. On the day, 3984189 shares were traded.
Ratios:
To gain a deeper understanding of LAB’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.26 and its Current Ratio is at 1.45. In the meantime, Its Debt-to-Equity ratio is 0.60 whereas as Long-Term Debt/Eq ratio is at 0.21.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on April 04, 2024, initiated with a Buy rating and assigned the stock a target price of $3.25.
On July 12, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $4.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 05 ’24 when Casdin Partners Master Fund, L bought 1,403 shares for $2.62 per share. The transaction valued at 3,669 led to the insider holds 11,497,928 shares of the business.
Casdin Partners Master Fund, L bought 250,000 shares of LAB for $642,500 on Mar 04 ’24. The Director now owns 11,496,525 shares after completing the transaction at $2.57 per share. On May 19 ’23, another insider, Casdin Eli, who serves as the Director of the company, bought 800,000 shares for $2.29 each. As a result, the insider paid 1,835,920 and bolstered with 1,200,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LAB now has a Market Capitalization of 1.12B and an Enterprise Value of 1.10B. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.52. Its current Enterprise Value per Revenue stands at 10.35 whereas that against EBITDA is -20.20.
Stock Price History:
Over the past 52 weeks, LAB has reached a high of $3.16, while it has fallen to a 52-week low of $1.46. The 50-Day Moving Average of the stock is 2.5388, while the 200-Day Moving Average is calculated to be 2.3870.
Shares Statistics:
It appears that LAB traded 2.05M shares on average per day over the past three months and 3.25M shares per day over the past ten days. A total of 383.05M shares are outstanding, with a floating share count of 373.22M. Insiders hold about 2.56% of the company’s shares, while institutions hold 48.33% stake in the company. Shares short for LAB as of Mar 15, 2024 were 9.26M with a Short Ratio of 4.53, compared to 8.06M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.19% and a Short% of Float of 3.40%.
Earnings Estimates
As of right now, 2 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.09 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.3 and -$0.43 for the fiscal current year, implying an average EPS of -$0.36. EPS for the following year is -$0.17, with 2 analysts recommending between -$0.15 and -$0.18.
Revenue Estimates
A total of 2 analysts have provided revenue estimates for LAB’s current fiscal year. The highest revenue estimate was $200.03M, while the lowest revenue estimate was $200M, resulting in an average revenue estimate of $200.02M. In the same quarter a year ago, actual revenue was $106.34M, up 88.10% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $230.99M in the next fiscal year. The high estimate is $235M and the low estimate is $226.98M. The average revenue growth estimate for next year is up 15.50% from the average revenue estimate for this year.
